Scilex Holding SCLX
NASDAQ SCLX
$5.73 -0.07 (-1.21%)
At close: Aug 21, 2026 · 4:00 PM EDT

Scilex Holding (SCLX) Liabilities and Shareholders Equity (2020 - 2026)

Scilex Holding (SCLX) posted quarterly Liabilities and Shareholders Equity of $293.6 million for Q1 2026, up 271.8% year-over-year from $79.0 million in Q1 2025, and down 19.55% quarter-over-quarter from $365.0 million in Q4 2025.

Scilex Holding (SCLX) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends

Scilex Holding's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $293.6 million for Q1 2026.

  • In Q1 2026, Liabilities and Shareholders Equity rose 271.8% year-over-year to $293.6 million; the TTM figure through Mar 2026 stood at $1.0 billion (up 170.16% YoY), while the FY2025 annual figure was $365.0 million, up 292.65% from the prior year.
  • Liabilities and Shareholders Equity for Q1 2026 stood at $293.6 million, down from $365.0 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $365.0 million in Q4 2025, with the low at $79.0 million in Q1 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $101.3 million (2023), against an average of $138.4 million.
  • The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity slumped 38.96% in 2023, then surged 292.65% in 2025.
  • Scilex Holding's Liabilities and Shareholders Equity stood at $86.5 million in 2022, then climbed by 17.08% to $101.3 million in 2023, then dropped by 8.25% to $93.0 million in 2024, then soared by 292.65% to $365.0 million in 2025, then retreated by 19.55% to $293.6 million in 2026.
  • Business Quant data shows SCLX's Liabilities and Shareholders Equity at $293.6 million in Q1 2026, $365.0 million in Q4 2025, and $275.9 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn 201.06 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn 135.12 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn 115.83 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn 49.36 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn 201.13 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn 82.83 Bn
10 Scilex Holding 39.22 Mn -73.57 Mn 3.97 Mn 253.56 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 293.64 Mn
Dec 31, 2025 364.98 Mn
Sep 30, 2025 275.88 Mn
Jun 30, 2025 83.76 Mn
Mar 31, 2025 78.98 Mn
Dec 31, 2024 92.95 Mn
Sep 30, 2024 100.43 Mn
Jun 30, 2024 104.54 Mn
Mar 31, 2024 91.24 Mn
Dec 31, 2023 101.31 Mn
Sep 30, 2023 80.53 Mn
Jun 30, 2023 126.46 Mn
Mar 31, 2023 86.05 Mn
Dec 31, 2022 86.53 Mn
Sep 30, 2022 101.46 Mn
Jun 30, 2022 142.30 Mn
Mar 31, 2022 140.97 Mn
Dec 31, 2021 77.93 Mn
Sep 30, 2021 139.64 Mn
Jun 30, 2021 139.90 Mn